{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:43:07Z","timestamp":1788594187853,"version":"build-2803163510"},"reference-count":91,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T00:00:00Z","timestamp":1607385600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAD"],"published-print":{"date-parts":[[2020,12,8]]},"abstract":"<jats:p>Background: Certain individuals, here referred to as Non-Demented with Alzheimer Neuropathology (NDAN), do not show overt neurodegeneration (N-) and remain cognitively intact despite the presence of plaques (A+) and tangles (T+) that would normally be consistent with fully symptomatic Alzheimer\u2019s disease (AD). Objective: The existence of NDAN (A\u200a+\u200aT+N-) subjects suggests that the human brain utilizes intrinsic mechanisms that can naturally evade cognitive decline normally associated with the symptomatic stages of AD (A\u200a+\u200aT+N+). Deciphering the underlying mechanisms would prove relevant to develop complementing therapeutics to prevent progression of AD-related cognitive decline. Methods: Previously, we have reported that NDAN present with preserved neurogenesis and synaptic integrity paralleled by absence of amyloid oligomers at synapses. Using postmortem brain samples from age-matched control subjects, demented AD patients and NDAN individuals, we performed immunofluorescence, western blots, micro transplantation of synaptic membranes in Xenopus oocytes followed by twin electrode voltage clamp electrophysiology and fluorescence assisted single synaptosome-long term potentiation studies. Results: We report decreased tau oligomers at synapses in the brains of NDAN subjects. Furthermore, using novel approaches we report, for the first time, that such absence of tau oligomers at synapses is associated with synaptic functional integrity in NDAN subjects as compared to demented AD patients. Conclusion: Overall, these results give further credence to tau oligomers as primary actors of synaptic destruction underscoring cognitive demise in AD and support their targeting as a viable therapeutic strategy for AD and related tauopathies.<\/jats:p>","DOI":"10.3233\/jad-200716","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T10:24:03Z","timestamp":1605263043000},"page":"1661-1678","source":"Crossref","is-referenced-by-count":54,"title":["Functional Integrity of Synapses in the Central Nervous System of Cognitively Intact Individuals with High Alzheimer\u2019s Disease Neuropathology Is Associated with Absence of Synaptic Tau Oligomers"],"prefix":"10.1177","volume":"78","author":[{"given":"Ayush","family":"Singh","sequence":"first","affiliation":[{"name":"Mitchell Center for Neurodegenerative Diseases, Department of Neurology, UTMB Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dyron","family":"Allen","sequence":"additional","affiliation":[{"name":"Mitchell Center for Neurodegenerative Diseases, Department of Neurology, UTMB Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Fracassi","sequence":"additional","affiliation":[{"name":"Mitchell Center for Neurodegenerative Diseases, Department of Neurology, UTMB Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Batbayar","family":"Tumurbaatar","sequence":"additional","affiliation":[{"name":"Mitchell Center for Neurodegenerative Diseases, Department of Neurology, UTMB Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandramouli","family":"Natarajan","sequence":"additional","affiliation":[{"name":"Mitchell Center for Neurodegenerative Diseases, Department of Neurology, UTMB Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scaduto","sequence":"additional","affiliation":[{"name":"Mitchell Center for Neurodegenerative Diseases, Department of Neurology, UTMB Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy","family":"Woltjer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oregon Health and Science University, Portland, OR, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakez","family":"Kayed","sequence":"additional","affiliation":[{"name":"Mitchell Center for Neurodegenerative Diseases, Department of Neurology, UTMB Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agenor","family":"Limon","sequence":"additional","affiliation":[{"name":"Mitchell Center for Neurodegenerative Diseases, Department of Neurology, UTMB Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji","family":"Krishnan","sequence":"additional","affiliation":[{"name":"Mitchell Center for Neurodegenerative Diseases, Department of Neurology, UTMB Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulio","family":"Taglialatela","sequence":"additional","affiliation":[{"name":"Mitchell Center for Neurodegenerative Diseases, Department of Neurology, UTMB Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"key":"10.3233\/JAD-200716_ref1","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","article-title":"Amyloid deposition as the central event in the aetiology of Alzheimer\u2019s disease","volume":"12","author":"Hardy","year":"1991","journal-title":"Trends Pharmacol Sci"},{"key":"10.3233\/JAD-200716_ref2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1750-3639.1991.tb00661.x","article-title":"Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections","volume":"1","author":"Braak","year":"1991","journal-title":"Brain Pathol"},{"key":"10.3233\/JAD-200716_ref3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-neuro-061010-113613","article-title":"Amyloid precursor protein processing and Alzheimer\u2019s disease","volume":"34","author":"O\u2019Brien","year":"2011","journal-title":"Annu Rev Neurosci"},{"key":"10.3233\/JAD-200716_ref4","doi-asserted-by":"crossref","unstructured":"(2019) 2019 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 15, 321\u2013387.","DOI":"10.1016\/j.jalz.2019.01.010"},{"key":"10.3233\/JAD-200716_ref5","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s13524-012-0193-x","article-title":"Bayesian probabilistic projections of life expectancy for all countries","volume":"50","author":"Raftery","year":"2013","journal-title":"Demography"},{"key":"10.3233\/JAD-200716_ref6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41583-019-0240-3","article-title":"Amyloid-\u03b2-independent regulators of tau pathology in Alzheimer disease","volume":"21","author":"van der Kant","year":"2020","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-200716_ref7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pneurobio.2015.07.003","article-title":"Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies","volume":"155","author":"Bourdenx","year":"2017","journal-title":"Prog Neurobiol"},{"key":"10.3233\/JAD-200716_ref8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuropharm.2013.09.018","article-title":"A role for tau at the synapse in Alzheimer\u2019s disease pathogenesis","volume":"76 Pt A","author":"Pooler","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-200716_ref9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.neuroscience.2012.05.050","article-title":"Synaptic changes in Alzheimer\u2019s disease and its models","volume":"251","author":"Pozueta","year":"2013","journal-title":"Neuroscience"},{"key":"10.3233\/JAD-200716_ref10","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/j.bbadis.2013.08.012","article-title":"Structural plasticity of dendritic spines: The underlying mechanisms and its dysregulation in brain disorders","volume":"1832","author":"Lai","year":"2013","journal-title":"Biochim Biophys Acta"},{"key":"10.3233\/JAD-200716_ref11","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2478\/s13380-012-0032-y","article-title":"Soluble forms of tau are toxic in Alzheimer\u2019s disease","volume":"3","author":"Kopeikina","year":"2012","journal-title":"Transl Neurosci"},{"key":"10.3233\/JAD-200716_ref12","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.neurobiolaging.2010.01.010","article-title":"Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study","volume":"32","author":"Kramer","year":"2011","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-200716_ref13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0002-9440(10)65184-X","article-title":"Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer\u2019s disease","volume":"155","author":"Lue","year":"1999","journal-title":"Am J Pathol"},{"key":"10.3233\/JAD-200716_ref14","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1212\/01.wnl.0000341273.18141.64","article-title":"Factors associated with resistance to dementia despite high Alzheimer disease pathology","volume":"72","author":"Erten-Lyons","year":"2009","journal-title":"Neurology"},{"key":"10.3233\/JAD-200716_ref15","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.neurobiolaging.2007.05.005","article-title":"Resistance to Alzheimer\u2019s pathology is associated with nuclear hypertrophy in neurons","volume":"28","author":"Riudavets","year":"2007","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-200716_ref16","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/NEN.0b013e3181772794","article-title":"Neuronal hypertrophy in asymptomatic Alzheimer disease","volume":"67","author":"Iacono","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-200716_ref17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1750-1326-7-23","article-title":"Absence of amyloid beta oligomers at the postsynapse and regulated synaptic Zn2+in cognitively intact aged individuals with Alzheimer\u2019s disease neuropathology","volume":"7","author":"Bjorklund","year":"2012","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-200716_ref18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: A practical approach","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-200716_ref19","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.2174\/1381612822666160518142110","article-title":"Non-demented individuals with Alzheimer\u2019s disease neuropathology: Resistance to cognitive decline may reveal new treatment strategies","volume":"22","author":"Zolochevska","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.3233\/JAD-200716_ref20","doi-asserted-by":"crossref","first-page":"27812","DOI":"10.1038\/srep27812","article-title":"Preserved neurogenesis in non-demented individuals with AD neuropathology","volume":"6","author":"Briley","year":"2016","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-200716_ref21","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s11064-011-0674-0","article-title":"Brain serum amyloid P levels are reduced in individuals that lack dementia while having Alzheimer\u2019s disease neuropathology","volume":"37","author":"Crawford","year":"2012","journal-title":"Neurochem Res"},{"key":"10.3233\/JAD-200716_ref22","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3233\/JAD-180179","article-title":"Postsynaptic proteome of non-demented individuals with Alzheimer\u2019s disease neuropathology","volume":"65","author":"Zolochevska","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.3233\/JAD-200716_ref23","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1523\/JNEUROSCI.0587-07.2007","article-title":"Accumulation of pathological tau species and memory loss in a conditional model of tauopathy","volume":"27","author":"Berger","year":"2007","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-200716_ref24","doi-asserted-by":"crossref","first-page":"10741","DOI":"10.1523\/JNEUROSCI.1065-09.2009","article-title":"Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology","volume":"29","author":"Polydoro","year":"2009","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-200716_ref25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1326-6-39","article-title":"Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice","volume":"6","author":"Lasagna-Reeves","year":"2011","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-200716_ref26","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s12031-011-9566-7","article-title":"Are tangles as toxic as they look?","volume":"45","author":"Spires-Jones","year":"2011","journal-title":"J Mol Neurosci"},{"key":"10.3233\/JAD-200716_ref27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","article-title":"Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model","volume":"53","author":"Yoshiyama","year":"2007","journal-title":"Neuron"},{"key":"10.3233\/JAD-200716_ref28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1042\/BST20120135","article-title":"What is the pathological significance of tau oligomers?","volume":"40","author":"Cowan Catherine","year":"2012","journal-title":"Biochem Soc Trans"},{"key":"10.3233\/JAD-200716_ref29","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1126\/science.1062382","article-title":"Tauopathy in Drosophila: Neuro degeneration without neurofibrillary tangles","volume":"293","author":"Wittmann","year":"2001","journal-title":"Science"},{"key":"10.3233\/JAD-200716_ref30","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1126\/science.1113694","article-title":"Tau suppression in a neurodegenerative mouse model improves memory function","volume":"309","author":"Santacruz","year":"2005","journal-title":"Science"},{"key":"10.3233\/JAD-200716_ref31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/00005072-199902000-00008","article-title":"Neurons may live for decades with neurofibrillary tangles","volume":"58","author":"Morsch","year":"1999","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-200716_ref32","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ana.410410106","article-title":"Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer\u2019s disease","volume":"41","author":"Gomez-Isla","year":"1997","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-200716_ref33","first-page":"91","article-title":"Do neuronal inclusions kill the cell?","volume":"59","author":"Terry","year":"2000","journal-title":"J Neural Transm Suppl"},{"key":"10.3233\/JAD-200716_ref34","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neures.2005.11.009","article-title":"Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer\u2019s disease","volume":"54","author":"Maeda","year":"2006","journal-title":"Neurosci Res"},{"key":"10.3233\/JAD-200716_ref35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.brainres.2008.03.043","article-title":"Non-tau based neuronal degeneration in Alzheimer\u2019s disease \u2013an immunocytochemical and quantitative study in the supragranular layers of the middle temporal neocortex","volume":"1213","author":"van de Nes","year":"2008","journal-title":"Brain Res"},{"key":"10.3233\/JAD-200716_ref36","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1038\/nature08890","article-title":"Caspase activation precedes and leads to tangles","volume":"464","author":"de Calignon","year":"2010","journal-title":"Nature"},{"key":"10.3233\/JAD-200716_ref37","doi-asserted-by":"crossref","first-page":"10278","DOI":"10.1073\/pnas.0401911101","article-title":"Template-assisted filament growth by parallel stacking of tau","volume":"101","author":"Margittai","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-200716_ref38","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1126\/science.1899488","article-title":"A68: A major subunit of paired helical filaments and derivatized forms of normal Tau","volume":"251","author":"Lee","year":"1991","journal-title":"Science"},{"key":"10.3233\/JAD-200716_ref39","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jneumeth.2011.09.008","article-title":"Selective, quantitative measurement of releasable synaptic zinc in human autopsy hippocampal brain tissue from Alzheimer\u2019s disease patients","volume":"203","author":"Bjorklund","year":"2012","journal-title":"J Neurosci Methods"},{"key":"10.3233\/JAD-200716_ref40","doi-asserted-by":"crossref","first-page":"10973","DOI":"10.1073\/pnas.0804386105","article-title":"Microtransplantation of neurotransmitter receptors from postmortem autistic brains to Xenopus oocytes","volume":"105","author":"Limon","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-200716_ref41","doi-asserted-by":"crossref","first-page":"10071","DOI":"10.1073\/pnas.1204606109","article-title":"Loss of functional GABA(A) receptors in the Alzheimer diseased brain","volume":"109","author":"Limon","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-200716_ref42","doi-asserted-by":"crossref","first-page":"E5078","DOI":"10.1073\/pnas.1514486112","article-title":"Synapse-specific IL-1 receptor subunit reconfiguration augments vulnerability to IL-1beta in the aged hippocampus","volume":"112","author":"Prieto","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-200716_ref43","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1523\/JNEUROSCI.2774-16.2016","article-title":"Pharmacological rescue of long-term potentiation in Alzheimer diseased synapses","volume":"37","author":"Prieto","year":"2017","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-200716_ref44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"10.3233\/JAD-200716_ref45","first-page":"631","article-title":"Cognitive impairment of Alzheimer\u2019s disease","volume":"5","author":"Folstein","year":"1983","journal-title":"Neurotoxicol Teratol"},{"key":"10.3233\/JAD-200716_ref46","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol"},{"key":"10.3233\/JAD-200716_ref47","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jneumeth.2016.01.006","article-title":"A method to determine insulin responsiveness in synaptosomes isolated from frozen brain tissue","volume":"261","author":"Franklin","year":"2016","journal-title":"J Neurosci Methods"},{"key":"10.3233\/JAD-200716_ref48","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/1097-4547(20000715)61:2<186::AID-JNR9>3.0.CO;2-X","article-title":"Quantitative characterization of crude synaptosomal fraction (P-2) components by flow cytometry","volume":"61","author":"Gylys","year":"2000","journal-title":"J Neurosci Res"},{"key":"10.3233\/JAD-200716_ref49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1002\/cyto.a.20031","article-title":"Enrichment of presynaptic and postsynaptic markers by size-based gating analysis of synaptosome preparations from rat and human cortex","volume":"60","author":"Gylys","year":"2004","journal-title":"Cytometry A"},{"key":"10.3233\/JAD-200716_ref50","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1073\/pnas.92.11.5224","article-title":"Incorporation of acetylcholine receptors and Cl- channels in Xenopus oocytes injected with Torpedo electroplaque membranes","volume":"92","author":"Marsal","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3233\/JAD-200716_ref51","doi-asserted-by":"crossref","first-page":"e13035","DOI":"10.1111\/acel.13035","article-title":"Tau oligomers mediate aggregation of RNA-binding proteins Musashi1 and Musashi2 inducing Lamin alteration","volume":"18","author":"Montalbano","year":"2019","journal-title":"Aging Cell"},{"key":"10.3233\/JAD-200716_ref52","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13024-016-0126-z","article-title":"Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy","volume":"11","author":"Congdon","year":"2016","journal-title":"Mol Neurodegener"},{"key":"10.3233\/JAD-200716_ref53","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1096\/fj.11-199851","article-title":"Identification of oligomers at early stages of tau aggregation in Alzheimer\u2019s disease","volume":"26","author":"Lasagna-Reeves","year":"2012","journal-title":"FASEB J"},{"key":"10.3233\/JAD-200716_ref54","doi-asserted-by":"crossref","first-page":"19393","DOI":"10.1038\/srep19393","article-title":"Extracellular tau oligomers produce an immediate impairment of LTP and memory","volume":"6","author":"Fa","year":"2016","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-200716_ref55","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.tics.2016.01.001","article-title":"The locus coeruleus: Essential for maintaining cognitive function and the aging brain","volume":"20","author":"Mather","year":"2016","journal-title":"Trends Cogn Sci"},{"key":"10.3233\/JAD-200716_ref56","doi-asserted-by":"crossref","first-page":"68","DOI":"10.2174\/1567205012666150921095924","article-title":"Noradrenergic system in Down syndrome and Alzheimer\u2019s disease a target for therapy","volume":"13","author":"Phillips","year":"2016","journal-title":"Curr Alzheimer Res"},{"key":"10.3233\/JAD-200716_ref57","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tins.2018.01.010","article-title":"Long road to ruin: Noradrenergic dysfunction in neurodegenerative disease","volume":"41","author":"Weinshenker","year":"2018","journal-title":"Trends Neurosci"},{"key":"10.3233\/JAD-200716_ref58","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/WCO.0b013e32835a3432","article-title":"Where, when, and in what form does sporadic Alzheimer\u2019s disease begin?","volume":"25","author":"Braak","year":"2012","journal-title":"Curr Opin Neurol"},{"key":"10.3233\/JAD-200716_ref59","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1097\/NEN.0b013e318232a379","article-title":"Stages of the pathologic process in Alzheimer disease: Age categories from 1 to 100 years","volume":"70","author":"Braak","year":"2011","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-200716_ref60","doi-asserted-by":"crossref","first-page":"9359","DOI":"10.1523\/JNEUROSCI.6761-10.2011","article-title":"Not all desensitizations are created equal: Physiological evidence that AMPA receptor desensitization differs for kainate and glutamate","volume":"31","author":"Levchenko-Lambert","year":"2011","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-200716_ref61","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/ana.410270502","article-title":"Synapse loss in frontal cortex biopsies in Alzheimer\u2019s disease: Correlation with cognitive severity","volume":"27","author":"DeKosky","year":"1990","journal-title":"Ann Neurol"},{"key":"10.3233\/JAD-200716_ref62","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.cell.2017.10.024","article-title":"Synaptic neurexin complexes: A molecular code for the logic of neural circuits","volume":"171","author":"Sudhof","year":"2017","journal-title":"Cell"},{"key":"10.3233\/JAD-200716_ref63","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.conb.2018.04.027","article-title":"Tau-mediated synaptic and neuronal dysfunction in neurodegenerative disease","volume":"51","author":"Tracy","year":"2018","journal-title":"Curr Opin Neurobiol"},{"key":"10.3233\/JAD-200716_ref65","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrn.2015.1","article-title":"Tau in physiology and pathology","volume":"17","author":"Wang","year":"2016","journal-title":"Nat Rev Neurosci"},{"key":"10.3233\/JAD-200716_ref66","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/nrneurol.2015.225","article-title":"Tau and neurodegenerative disease: The story so far","volume":"12","author":"Iqbal","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.3233\/JAD-200716_ref67","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1146\/annurev.neuro.24.1.1121","article-title":"Neurodegenerative tauopathies","volume":"24","author":"Lee","year":"2001","journal-title":"Annu Rev Neurosci"},{"key":"10.3233\/JAD-200716_ref68","first-page":"464","article-title":"Frontotemporal dementias","volume":"22","author":"Finger","year":"2016","journal-title":"Continuum (Minneap Minn)"},{"key":"10.3233\/JAD-200716_ref69","doi-asserted-by":"crossref","first-page":"23063","DOI":"10.1074\/jbc.M111.237974","article-title":"Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease","volume":"286","author":"Patterson","year":"2011","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-200716_ref70","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/j.1471-4159.2011.07447.x","article-title":"Dysregulated phosphorylation of Ca(2+) \/calmodulin-dependent protein kinase II-alpha in the hippocampus of subjects with mild cognitive impairment and Alzheimer\u2019s disease","volume":"119","author":"Reese","year":"2011","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-200716_ref71","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s12035-018-1248-9","article-title":"Near infrared light treatment reduces synaptic levels of toxic tau oligomers in two transgenic mouse models of human tauopathies","volume":"56","author":"Comerota","year":"2019","journal-title":"Mol Neurobiol"},{"key":"10.3233\/JAD-200716_ref72","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.trci.2018.01.002","article-title":"Elevated phospholipase D isoform 1 in Alzheimer\u2019s disease patients\u2019 hippocampus: Relevance to synaptic dysfunction and memory deficits","volume":"4","author":"Krishnan","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.3233\/JAD-200716_ref73","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1046\/j.1471-4159.2003.02196.x","article-title":"Amyloid-\u03b2-induced toxicity of primary neurons is dependent upon differentiation-associated increases in tau and cyclin-dependent kinase 5 expression","volume":"88","author":"Liu","year":"2004","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-200716_ref74","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1126\/science.1141736","article-title":"Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer\u2019s disease mouse model","volume":"316","author":"Roberson","year":"2007","journal-title":"Science"},{"key":"10.3233\/JAD-200716_ref75","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1523\/JNEUROSCI.4152-10.2011","article-title":"Amyloid-\u03b2\/Fyn\u2013induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer\u2019s disease","volume":"31","author":"Roberson","year":"2011","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-200716_ref76","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1523\/JNEUROSCI.3191-12.2013","article-title":"Tau loss attenuates neuronal network hyperexcitability in mouse and} genetic models of epilepsy","volume":"33","author":"Holth","year":"2013","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-200716_ref77","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1523\/JNEUROSCI.2880-19.2020","article-title":"Selective disruption of inhibitory synapses leading to neuronal hyperexcitability at an early stage of tau pathogenesis in a mouse model","volume":"40","author":"Shimojo","year":"2020","journal-title":"J Neurosci"},{"key":"10.3233\/JAD-200716_ref78","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/s41598-018-19154-y","article-title":"Moderate decline in select synaptic markers in the prefrontal cortex (BA9) of patients with Alzheimer\u2019s disease at various cognitive stages","volume":"8","author":"Poirel","year":"2018","journal-title":"Sci Rep"},{"key":"10.3233\/JAD-200716_ref79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/BF01245715","article-title":"Loss of cortical GABA uptake sites in Alzheimer\u2019s disease","volume":"71","author":"Simpson","year":"1988","journal-title":"J Neural Transm"},{"key":"10.3233\/JAD-200716_ref80","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0197-4580(00)00183-4","article-title":"Cognitive and behavioral heterogeneity in Alzheimer\u2019s disease: Seeking the neurobiological basis","volume":"21","author":"Cummings","year":"2000","journal-title":"Neurobiol Aging"},{"key":"10.3233\/JAD-200716_ref81","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.neuron.2017.04.009","article-title":"Structural and functional architecture of AMPA-type glutamate receptors and their auxiliary proteins","volume":"94","author":"Greger","year":"2017","journal-title":"Neuron"},{"key":"10.3233\/JAD-200716_ref82","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3389\/fnmol.2017.00214","article-title":"Different forms of AMPA receptor mediated LTP and their correlation to the spatial working memory formation","volume":"10","author":"Shimshek","year":"2017","journal-title":"Front Mol Neurosci"},{"key":"10.3233\/JAD-200716_ref83","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.neuron.2018.10.018","article-title":"The AMPA receptor code of synaptic plasticity","volume":"100","author":"Diering","year":"2018","journal-title":"Neuron"},{"key":"10.3233\/JAD-200716_ref84","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1097\/00005072-200606000-00007","article-title":"Differential expression of synaptic proteins in the frontal and temporal cortex of elderly subjects with mild cognitive impairment","volume":"65","author":"Counts","year":"2006","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JAD-200716_ref85","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/j.1471-4159.2011.07337.x","article-title":"Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain","volume":"118","author":"Boutajangout","year":"2011","journal-title":"J Neurochem"},{"key":"10.3233\/JAD-200716_ref86","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.M111.229633","article-title":"Passive immunization with anti-tau antibodies in two transgenic models: Reduction of tau pathology and delay of disease progression","volume":"286,","author":"Chai","year":"2011","journal-title":"J Biol Chem"},{"key":"10.3233\/JAD-200716_ref87","first-page":"19","article-title":"Immunotherapy for the treatment of Alzheimer\u2019s disease: Amyloid-\u03b2 or tau, which is the right target?","volume":"3","author":"Castillo-Carranza","year":"2014","journal-title":"Immunotargets Ther"},{"key":"10.3233\/JAD-200716_ref88","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1080\/13543784.2019.1619694","article-title":"Tau immunotherapies for Alzheimer\u2019s disease","volume":"28","author":"Hoskin","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"10.3233\/JAD-200716_ref89","doi-asserted-by":"crossref","first-page":"108104","DOI":"10.1016\/j.neuropharm.2020.108104","article-title":"Tau immunotherapies: Lessons learned, current status and future considerations","volume":"175","author":"Sandusky-Beltran","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.3233\/JAD-200716_ref90","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/bs.pmbts.2019.06.001","article-title":"Alzheimer\u2019s therapy development: A few points to consider","volume":"168","author":"Sigurdsson","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"10.3233\/JAD-200716_ref91","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.molmed.2015.03.003","article-title":"Tau immunotherapy for Alzheimer\u2019s disease","volume":"21","author":"Pedersen","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.3233\/JAD-200716_ref92","doi-asserted-by":"crossref","first-page":"798","DOI":"10.3389\/fnins.2018.00798","article-title":"Ten years of tau-targeted immunotherapy: The path walked and the roads ahead","volume":"12","author":"Novak","year":"2018","journal-title":"Front Neurosci"}],"container-title":["Journal of Alzheimer's Disease"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JAD-200716","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:04:24Z","timestamp":1777370664000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JAD-200716"}},"subtitle":[],"editor":[{"given":"Jose","family":"Abisambra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,12,8]]},"references-count":91,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jad-200716","relation":{},"ISSN":["1387-2877","1875-8908"],"issn-type":[{"value":"1387-2877","type":"print"},{"value":"1875-8908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,8]]}}}